Analysts Issue Forecasts for ASMB FY2029 Earnings

Assembly Biosciences, Inc. (NASDAQ:ASMB) – Research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Assembly Biosciences in a note issued to investors on Monday, March 24th. HC Wainwright analyst E. Arce expects that the biopharmaceutical company will earn ($12.58) per share for the year. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Assembly Biosciences’ current full-year earnings is ($6.87) per share.

ASMB has been the topic of several other reports. Guggenheim initiated coverage on Assembly Biosciences in a research note on Tuesday. They issued a “buy” rating and a $31.00 price objective on the stock. StockNews.com lowered Assembly Biosciences from a “buy” rating to a “hold” rating in a research note on Monday.

Assembly Biosciences Stock Down 5.3 %

NASDAQ ASMB opened at $10.81 on Tuesday. The stock has a market cap of $68.71 million, a P/E ratio of -1.61 and a beta of 0.62. Assembly Biosciences has a twelve month low of $10.27 and a twelve month high of $19.93. The company’s 50-day simple moving average is $12.70 and its 200 day simple moving average is $15.02.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($1.57) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.75) by $0.18. Assembly Biosciences had a negative net margin of 144.05% and a negative return on equity of 121.46%. The firm had revenue of $7.36 million for the quarter, compared to analyst estimates of $7.05 million.

Insiders Place Their Bets

In other Assembly Biosciences news, Director Michael Houghton acquired 3,202 shares of Assembly Biosciences stock in a transaction on Monday, December 30th. The shares were bought at an average price of $15.61 per share, with a total value of $49,983.22. Following the completion of the purchase, the director now owns 3,202 shares in the company, valued at $49,983.22. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Marshall Wace LLP grew its holdings in Assembly Biosciences by 16.5% during the 4th quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company’s stock worth $234,000 after acquiring an additional 2,098 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Assembly Biosciences by 5,137.3% during the third quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 3,442 shares during the last quarter. FMR LLC increased its holdings in shares of Assembly Biosciences by 29.7% in the third quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 3,635 shares in the last quarter. Palumbo Wealth Management LLC bought a new position in Assembly Biosciences in the 4th quarter worth approximately $180,000. Finally, Man Group plc bought a new position in Assembly Biosciences in the 4th quarter worth approximately $309,000. 19.92% of the stock is owned by institutional investors.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.